Lantheus Holdings

What Lantheus Holdings does

Lantheus Holdings is a Bedford, Massachusetts-based radiopharmaceutical company that develops, manufactures, and commercializes diagnostic imaging agents and therapeutic radiopharmaceuticals. Founded in 1956 (originally as New England Nuclear Corporation), the company is publicly traded on NASDAQ under the ticker LNTH and operates with over 1,000 employees across the U.S., Canada, Germany, Sweden, Switzerland, and the U.K. Its core technology combines radioactive isotopes with targeting molecules to produce PET and SPECT imaging agents, as well as Lu-177-based therapeutic radiopharmaceuticals.

The commercial portfolio centers on PYLARIFY (piflufolastat F 18), the leading PSMA PET imaging agent for prostate cancer in the U.S. (generating over $240 million in Q4 2025 revenue), and DEFINITY, an ultrasound contrast agent for echocardiography. The pipeline includes the newly approved PYLARIFY TruVu (higher-throughput reformulation), PNT2003 (Lutetium Lu 177 Dotatate for GEP-NETs, tentative FDA approval), MK-6240 (Tau PET for Alzheimer's, August 2026 PDUFA), LNTH-2501/OCTEVY (Ga 68 edotreotide for neuroendocrine tumors, currently subject to an FDA Complete Response Letter), and LNTH-2513/18F-GP1 (DVT imaging). The company has built an integrated theranostics platform spanning diagnostic imaging and therapeutic radiopharmaceuticals, supplemented by AI-enabled image analysis tools (PYLARIFY AI, CURE8) and a CDMO business acquired through Evergreen Theragnostics.

Revenue is generated primarily through one-time product sales of FDA-approved diagnostic and therapeutic radiopharmaceuticals to hospitals, imaging centers, and healthcare providers, distributed via direct sales, an e-commerce portal, and international distributors. The company also derives revenue from Pharma Solutions partnerships providing clinical trial manufacturing support to pharmaceutical companies. In 2026 the company is weighing an unsolicited ~$7 billion takeover offer from Curium Pharma while operating under Interim CEO Mary Anne Heino following the end-of-2025 retirement of CEO Brian Markison and departure of President Paul Blanchfield.

Name

Lantheus Holdings

Legal name

Lantheus Holdings, Inc.

Website

http://www.lantheus.com/

Company type

Public

Founded year

1956

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Lantheus Holdings is a publicly traded radiopharmaceutical company that develops and commercializes diagnostic imaging agents and therapeutic radiopharmaceuticals for oncology, neurology, and cardiology, serving hospitals, imaging centers, and pharmaceutical partners globally.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Diagnostic Radiopharmaceuticals (SPECT/PET Tracers) (HLAIAGAA)

Keywords

• Diagnostic imaging agents
• Radiopharmaceutical therapeutics
• PET imaging agents
• PSMA imaging diagnostics
• Nuclear medicine products

Headquarters

HQ city

North Billerica

HQ country

United States

HQ region

North America

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Product Sales - Diagnostic Imaging Agents: Lantheus generates revenue primarily through the sale of FDA-approved diagnostic imaging agents including PYLARIFY (piflufolastat F 18), DEFINITY, and Neuraceq. These radiopharmaceutical products are sold to hospitals, imaging centers, and healthcare providers for diagnostic procedures.
2. Therapeutic Radiopharmaceuticals: Revenue from co-commercialization and future sales of therapeutic radiopharmaceutical products including PNT2003 (Lutetium Lu 177 Dotatate) and potential future therapeutic candidates.
3. Contract Manufacturing / CDMO Services: Revenue from manufacturing services through Evergreen Theragnostics CDMO capabilities, providing radiopharmaceutical manufacturing services to pharmaceutical partners.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Lantheus develops, manufactures, and commercializes diagnostic imaging agents and therapeutic radiopharmaceuticals for oncology, neurology, and cardiology. The commercial portfolio centers on PYLARIFY (PSMA PET imaging for prostate cancer) and DEFINITY (ultrasound contrast agent), with recent launches including PYLARIFY TruVu and PNT2003, plus Neuraceq for Alzheimer's imaging. The company also offers CDMO services through its Evergreen Theragnostics subsidiary.

Product overview

Lantheus Holdings is a radiopharmaceutical-focused company offering a portfolio of diagnostic imaging agents and radiopharmaceutical products. The core portfolio includes PYLARIFY (PSMA PET for prostate cancer) and DEFINITY (ultrasound contrast agent), supplemented by the acquired Neuraceq amyloid imaging agent. Key pipeline products include PYLARIFY TruVu (higher-throughput reformulation), PNT2003 (Lutetium-based neuroendocrine tumor treatment), MK-6240 (Tau PET for Alzheimer's), LNTH-2501/OCTEVY (neuroendocrine tumor diagnostic), and LNTH-2513 (DVT imaging). The company is pivoting toward PET radiodiagnostics while divesting SPECT assets, and offers AI-enabled analysis tools through its PYLARIFY AI platform.

Differentiator

Problem solved

Functional benefit

Brands

• PYLARIFY: PSMA PET imaging agent for prostate cancer detection
• PYLARIFY TruVu
• DEFINITY
• NeuraCeq
• PYLARIFY AI
• CURE8
• PNT2003
• LNTH-2501 (OCTEVY)
• LNTH-2513 (18F-GP1)

Quantifiable outcome

• PYLARIFY showed strong Q4 2025 performance with over $240 million in quarterly revenue despite competitive pressures.
• +2 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• SHINE TechnologiescoreStrategic or Co-development Partner · 1 January 2026SHINE Technologies acquired Lantheus's SPECT isotope distribution business in January 2026 for approximately $240 million in Series E funding led by Dr. Patrick Soon-Shiong. The transaction includes supply agreements for Lu-177 isotopes. SHINE also raised $240 million in Series E with Dr. Patrick Soon-Shiong joining the board.
• GE HealthcareminorStrategic or Co-development Partner · 1 January 2026Development opportunities in cardiac imaging agents partnered with GE Healthcare. Lantheus is pursuing cardiac imaging applications leveraging its radiopharmaceutical platform.
• Academic and Pharmaceutical PartnersminorStrategic or Co-development Partner · 1 January 2026Pharma Solutions partnerships supporting global clinical trials across oncology, neurology and cardiology. Lantheus provides radiopharmaceutical manufacturing and clinical trial support services to pharmaceutical companies.
• Enigma Biomedical USAcoreTechnology or Integration · 1 October 2025Enigma Biomedical USA announced FDA acceptance of NDA for florquinitau F-18 (MK-6240), a Tau PET radiodiagnostic for Alzheimer's disease, with target action date of August 13, 2026. Lantheus holds commercial rights to MK-6240 following its 2023 acquisition of Cerveau Technologies.
• Life Healthcare (Life Molecular Imaging)coreStrategic or Co-development Partner · 1 July 2025Lantheus acquired Life Molecular Imaging (LMI) unit from South African healthcare group Life Healthcare in 2025. The acquisition included an upfront payment and potential milestone payments. LMI brings Neuraceq (amyloid-beta PET imaging agent) and additional pipeline assets for Alzheimer's diagnostics.
• Evergreen TheragnosticscoreStrategic or Co-development Partner · 1 January 2025Lantheus acquired Evergreen Theragnostics for $250 million upfront with potential additional milestone payments of up to $752.5 million. Evergreen provides CDMO (contract development and manufacturing organization) services for radiopharmaceuticals, expanding Lantheus's manufacturing capabilities.
• Cerveau TechnologiescoreTechnology or Integration · 6 February 2023Lantheus acquired Cerveau Technologies, a Knoxville-based developer of PET imaging agents including MK-6240, a tau-detecting agent for Alzheimer's disease. MK-6240 is in clinical development and being used in over 60 trials worldwide by more than 16 pharmaceutical companies. Deal involved upfront, milestone, and royalty arrangements.
• POINT Biopharma Global, Inc.coreTechnology or Integration · 1 December 2022Lantheus licensed exclusive worldwide rights to PNT2003 (Lutetium Lu 177 Dotatate) from POINT Biopharma Global in December 2022. POINT Biopharma was subsequently acquired by Eli Lilly and Company in December 2023, with Lantheus maintaining its licensing agreement.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Novartis: Novartis owns Advanced Accelerator Applications and markets LUTATHERA and Pluvicto, the direct competitive anchors in the neuroendocrine tumor and PSMA-lutetium therapeutic spaces. Lantheus's PNT2003 is positioned as a radioequivalent to LUTATHERA, making Novartis its closest head-to-head peer in radiopharmaceuticals.
• Telix Pharmaceuticals: Telix markets Illuccix (Ga-68 PSMA-11), the principal US competitor to Lantheus's PYLARIFY in prostate cancer PSMA PET imaging. Telix also has a broader theranostic pipeline including TLX591 (177Lu-rosopatamab) and is a direct competitor in multiple radiopharmaceutical indications.
• Curium Pharma: PE-backed Curium is a vertically integrated radiopharmaceutical manufacturer with a portfolio of diagnostic and therapeutic products across SPECT, PET, and oncology. It is currently the would-be acquirer of Lantheus at a ~$7B valuation and competes in radiopharmacy, neuroendocrine, and prostate cancer imaging.
• Bracco Imaging: Bracco is a privately held diagnostic imaging company with a portfolio of contrast agents and emerging radiopharmaceuticals, including partnerships in PSMA and oncology imaging. It directly competes with Lantheus in contrast-enhanced ultrasound (vs. DEFINITY) and is expanding into molecular imaging.

Broad incumbents

• Bayer: Bayer historically operated a major diagnostic imaging business (Piramal/Life Molecular Imaging lineage) and retains broader pharma scale. Lantheus's Head of R&D, Ludger Dinkelborg, came from Bayer, and Bayer's Molecular Imaging division historically competed with Neuraceq's predecessor products.
• GE HealthCare: GE HealthCare is a major medical imaging equipment vendor with growing pharmaceutical diagnostics and radiopharmaceutical partnerships. Lantheus has an active cardiac imaging partnership with GE HealthCare, and the two compete and collaborate across the molecular imaging value chain.
• Siemens Healthineers: Siemens Healthineers is a global medical imaging equipment leader whose PET/CT scanners and software platforms underpin nuclear medicine workflows. As a broad incumbent, it competes with Lantheus-adjacent imaging informatics and serves as a key channel for adoption of PSMA, amyloid, and tau PET imaging.
• Philips: Philips is a major medical imaging and healthcare IT incumbent with PET and SPECT scanner systems that enable the diagnostic workflows in which Lantheus's radiopharmaceuticals are used. As a broad incumbent, Philips competes and partners across the molecular imaging ecosystem.

Others

• Eli Lilly: Lilly acquired POINT Biopharma Global (December 2023), which originally licensed PNT2003 to Lantheus. Lilly is the upstream originator/partner for one of Lantheus's key therapeutic assets and is a peer via that licensing arrangement rather than direct product overlap.

Emerging players

• ITM (Isotope Technologies Munich): ITM is a German privately held radiopharmaceutical company developing both diagnostic and therapeutic radionuclide-based products in oncology, including Lu-177-based candidates. It competes with Lantheus in targeted radionuclide therapy and represents an emerging European peer in the space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lantheus-medical-imaging

Revenue estimate

Valuation estimate

Number of profiles

Profiles24 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lantheus Holdings